Market Snapshot

BSE Sensex: 83576.24 -0.72%
BSE 500: 36807.62 -0.89%
BSE 200: 11620.53 -0.79%
BSE 100: 26904.82 -0.73%
BSE MidCap: 46304.8 -0.90%
BSE SmallCap: 49912.11 -1.74%
BSE BANKEX: 66616.92 -0.58%
BSE IT: 36795.24 0.03%
Nifty 50: 25683.3 -0.75%
Nifty 500: 23467.35 -0.90%
Nifty 200: 14306.95 -0.79%
Nifty 100: 26252.95 -0.79%
Nifty Midcap 100: 59748.15 -0.79%
Nifty Small 100: 17282.65 -1.81%
Nifty IT: 38027.2 0.28%
Nifty PSU Bank: 8601.05 0.18%

News:

Protean eGov Technologies bags...
PTC Industries? arm secures ma...
Globus Spirits reports multi-f...
IREDA Q3 PAT jumps 15% YoY to ...
Tejas Networks reports dismal ...

Concord Biotech Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

09 Jan 2026 | 03:59 PM

1,320.80

-25.85 (-1.92%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

-41.44%

Return (1Y)

Underperformed BSE Healthcare by 38.98%
More Volatile

2.75%

Standard Deviation (1Y)

Higher than BSE Healthcare by 1.79%
Inconsistent Performer

2/12

Months

underperformed BSE Healthcare
AxisDirect View

No View

52 Week High-Low

2,452

1,297

News & Announcements

Concord Biotech appoints Raviraj Karia as CFO
25 days ago

Concord Biotech appoints Raviraj Karia as CFO

18 - Dec - 2025 12:00 | 25 days ago

Raviraj Karia is a chartered accountant and senior finance leader with more than 23 years of experience across pharmaceuticals, healthcare, clinical research, logistics, and private equity. His career reflects deep expertise in corporate governance, strategic finance, and business partnering, having worked closely with Boards, Promoters, CEOs, and global leadership teams.
Across leadership roles at Intas Pharmaceuticals, Sakar Healthcare, Lambda Therapeutics, Shalby Hospitals, Gati, GVFL, and Claris Lifesciences, he has delivered significant impact?managing multi billion dollar financing programs, leading India?s largest outbound pharma acquisition, facilitating marquee private equity investments, and executing global audits across Europe, the US, Latin America, and emerging markets.
Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.
The company?s consolidated net profit declined 33.6% to Rs 63.58 crore on 20.3% increase in net sales to Rs 247.06 crore in Q2 FY26 over Q2 FY25.
The scrip rose 0.20% to Rs 1335 on the BSE.
Powered by Capital Market - Live News
Concord Biotech consolidated net profit declines 33.59% in the September 2025 quarter
58 days ago

Concord Biotech consolidated net profit declines 33.59% in the September 2025 quarter

15 - Nov - 2025 12:00 | 58 days ago

Net profit of Concord Biotech declined 33.59% to Rs 63.58 crore in the quarter ended September 2025 as against Rs 95.74 crore during the previous quarter ended September 2024. Sales declined 20.35% to Rs 247.06 crore in the quarter ended September 2025 as against Rs 310.18 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 247.06 310.18 -20

OPM % 35.82 43.11 -

PBDT 104.08 143.65 -28

PBT 85.68 130.34 -34

NP 63.58 95.74 -34

Powered by Capital Market - Live News
Concord Biotech standalone net profit declines 36.27% in the September 2025 quarter
58 days ago

Concord Biotech standalone net profit declines 36.27% in the September 2025 quarter

15 - Nov - 2025 12:00 | 58 days ago

Net profit of Concord Biotech declined 36.27% to Rs 62.90 crore in the quarter ended September 2025 as against Rs 98.70 crore during the previous quarter ended September 2024. Sales declined 20.35% to Rs 247.06 crore in the quarter ended September 2025 as against Rs 310.18 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 247.06 310.18 -20

OPM % 36.65 44.06 -

PBDT 103.92 146.60 -29

PBT 85.53 133.29 -36

NP 62.90 98.70 -36

Powered by Capital Market - Live News
Concord Biotech announces board meeting date
65 days ago

Concord Biotech announces board meeting date

08 - Nov - 2025 12:00 | 65 days ago

Concord Biotech will hold a meeting of the Board of Directors of the Company on 13 November 2025.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Concord Biotech Ltd is trading very close to its 52 Week Low
FII shareholding in Concord Biotech Ltd has decreased by -11.79% since past 3 Months
MF shareholding in Concord Biotech Ltd has decreased by -3.26% since past 3 Months
MF shareholding in Concord Biotech Ltd has decreased by -8.83% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	247.06	310.18	-20
OPM %	35.82	43.11	-
PBDT	104.08	143.65	-28
PBT	85.68	130.34	-34
NP	63.58	95.74	-34

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	247.06	310.18	-20
OPM %	36.65	44.06	-
PBDT	103.92	146.60	-29
PBT	85.53	133.29	-36
NP	62.90	98.70	-36

General Notifications

My Notifications

Research Notifications

Concord Biotech Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

1,320.80 -25.85 (-1.92%)

News & Announcements

Price vs Volume

Stock Trivia

Concord Biotech Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

1,320.80

-25.85 (-1.92%)